长链非编码RNA MEG3在肿瘤中的研究

doi:10.3760/cma.j.issn.1673-422X.2015.02.010

摘要/Abstract

摘要： 母源性印记基因3（MEG3）是一种肿瘤抑制基因，其转录产物不编码蛋白，属长链非编码RNA。在人类多种肿瘤组织及细胞株中存在MEG3基因表达缺失，DNA甲基化程度升高等机制与之密切相关。研究表明，MEG3基因及其转录产物能够抑制肿瘤细胞增殖，并促进肿瘤细胞凋亡，其抑癌机制与肿瘤抑制基因p53的作用密不可分。

关键词: 肿瘤, 非编码RNA, 母源性印记基因3

Abstract: Maternally expressed gene 3 (MEG3) is a tumorsuppressing gene, and MEG3 RNAs, its products, are a series of long noncoding RNAs. The MEG3 gene is lost in kinds of human tumors, further more, the methylation of related DNA region is directly associated with the deficiency of MEG3 expression. Studies show that MEG3 gene and MEG3 RNAs can inhibit cell proliferation and induce apoptosis, which is associated with the fuction of tumor suppressor gene p53.

Key words: Neoplasms, Non-coding RNA, Maternally expressed gene 3

陈瑞东,唐文,胡端敏. 长链非编码RNA MEG3在肿瘤中的研究[J]. 国际肿瘤学杂志, 2015, 42(2): 118-121.

Chen Ruidong, Tang Wen, Hu Duanmin. Research progress of MEG3 long noncoding RNA[J]. Journal of International Oncology, 2015, 42(2): 118-121.

参考文献

［1］ Gibb EA, Brown CJ, Lam WL. The functional role of long noncoding RNA in human carcinomas［J］. Mol Cancer, 2011, 10: 38. ［2］ Miyoshi N, Wagatsuma H, Wakana S, et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q［J］. Genes Cells, 2000, 5(3): 211-220. ［3］ Zhang X, Zhou Y, Mehta KR, et al. A pituitaryderived MEG3 isoform functions as a growth suppressor in tumor cells［J］. J Clin Endocrinol Metab, 2003, 88(11): 5119-5126. ［4］ Zhang X, Gejman R, Mahta A, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression［J］. Cancer Res, 2010, 70(6): 2350-2358. ［5］ Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 noncoding RNA［J］. J Biol Chem, 2007, 282(34): 24731-24742. ［6］ Braconi C, Kogure T, Valeri N, et al. microRNA29 can regulate expression of the long noncoding RNA gene MEG3 in hepatocellular cancer［J］. Oncogene, 2011, 30(47): 4750-4756. ［7］ Wang P, Ren Z, Sun P. Overexpression of the long noncoding RNA MEG3 impairs in vitro glioma cell proliferation［J］. J Cell Biochem, 2012, 113(6): 1868-1874. ［8］ Lu KH, Li W, Liu XH, et al. Long noncoding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression［J］. BMC Cancer, 2013, 13: 461. ［9］ Qin R, Chen Z, Ding Y, et al. Long noncoding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis［J］. Neoplasma, 2013, 60(5): 486-492. ［10］ Astuti D, Latif F, Wagner K, et al. Epigenetic alteration at the DLK1GTL2 imprinted domain in human neoplasia:analysis of neuroblastoma, phaeochromocytoma and Wilms′ tumour［J］. Br J Cancer, 2005, 92(8): 1574-1580. ［11］ Zhao J, Dahle D, Zhou Y, et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors［J］. J Clin Endocrinol Metab, 2005, 90(4): 2179-2186. ［12］ Kagami M, O′Sullivan MJ, Green AJ, et al. The IGDMR and the MEG3DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers［J］. PLoS Genet, 2010, 6(6): e1000992. ［13］ Paulsen M, Takada S, Youngson NA, et al. Comparative sequence analysis of the imprinted Dlk1Gtl2 locus in three mammalian species reveals highly conserved genomic elements and refines comparison with the Igf2H19 region［J］.Genome Res, 2001, 11(12): 2085-2094. ［14］ Takada S, Paulsen M, Tevendale M, et al. Epigenetic analysis of the Dlk1Gtl2 imprinted domain on mouse chromosome 12: implicationsfor imprinting control from comparison with Igf2H19［J］. Hum Mol Genet, 2002, 11(1): 77-86. ［15］ Zhao J, Zhang X, Zhou Y, et al. Cyclic AMP stimulates MEG3 gene expression in cells through a cAMPresponse element (CRE) in the MEG3 proximal promoter region［J］. Int J Biochem Cell Biol, 2006, 38(10): 1808-1820. ［16］ Gejman R, Batista DL, Zhong Y, et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas［J］. J Clin Endocrinol Metab, 2008, 93(10): 4119-4125. ［17］ Sun M , Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer［J］. Tumour Biol, 2014, 35(2): 1065-1073. ［18］ Zhang X, Rice K, Wang Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions［J］. Endocrinology, 2010, 151(3): 939-947. ［19］ Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer［J］. Mol Biosyst, 2013, 9(3): 407-411. ［20］ Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use［J］. Cold Spring Harb Perspect Biol, 2010, 2(1): a001008. ［21］ Vousden KH, Prives C. Blinded by the light: the growing complexity of p53［J］. Cell, 2009, 137(3): 413-431. ［22］ Brooks CL, Gu W. p53 regulation by ubiquitin［J］. FEBS Lett, 2011, 585(18): 2803-2809. ［23］ Ayroldi E, Petrillo MG, Bastianelli A, et al. LGILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells［J］. Cell Death Differ, 2014, In press. ［24］ Chao CC. Mechanisms of p53 degradation［J］. Clin Chim Acta, 2014, 438C: 139-147. ［25］ Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops［J］. Oncogene, 2005, 24(17): 2899-2908. ［26］ Johnson R. Long noncoding RNAs in Huntington′s disease neurodegeneration［J］. Neurobiol Dis, 2012, 46(2): 245-254.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.